# Rodeo Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/rodeo-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Seattle, US
- Website: www.rodeotherapeutics.com
- Total disclosed funding: $5.9M
- Latest round: Series A (Jul 25, 2017)
- Investors on record: 9

## About

Rodeo Therapeutics Corp. operates in the digital real estate sector, specializing in domain name acquisition and leasing to facilitate online presence for businesses and individuals.Founded in 2017 and headquartered in Seattle, US, Rodeo Therapeutics Corp. focuses on domain name acquisition and leasing. The company has completed a total of 3 deals, with its most recent deal occurring on March 30, 2021, involving a TRADE SALE to Amgen Inc. for USD 55.00 mn. The total amount raised by the company is USD 55.00 mn.Rodeo Therapeutics specializes in domain name acquisition and leasing, offering a high-value domain, rodeotherapeutics.com, available for outright purchase at USD 9,995 or through a lease-to-own option at USD 480 per month. These services are designed to help individuals and businesses enhance their online presence while ensuring secure and efficient domain transfers, catering to both the US market and international clients.Rodeo Therapeutics generates revenue through direct sales and leasing agreements for its domain names, with options for outright purchase or lease-to-own arrangements. The company’s clear pricing structure promotes secure transactions, allowing for a consistent revenue stream through monthly payments, which supports both small businesses and larger enterprises in investing in their digital assets.Following the TRADE SALE agreement with Amgen Inc. in March 2021, Rodeo Therapeutics plans to utilize the proceeds to expand its service offerings and explore new markets. Future initiatives may include the introduction of additional high-value domains aimed at various sectors and geographic regions. The strategic focus is on enhancing customer support and streamlining the acquisition process, with the objective of broadening its international reach.

## Funding rounds

- Series A, Jul 25, 2017, $5.9M — ARCH Venture Partners, Alexandria Venture Investments, Johnson & Johnson Innovation, WRF Capital, AbbVie Ventures, Accelerator Life Science Partners, Eli Lilly & Company, Watson Fund, Wuxi AppTec Group

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series A
- WRF Capital (https://capitalatlas.ai/funds/wrf-capital) — Series A
- AbbVie Ventures (https://capitalatlas.ai/funds/abbvie-ventures) — Series A
- Accelerator Life Science Partners (https://capitalatlas.ai/funds/accelerator-life-science-partners) — Series A
- Eli Lilly & Company — Series A
- Watson Fund (https://capitalatlas.ai/funds/watson-fund) — Series A
- Wuxi AppTec Group — Series A